Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 176

Similar articles for PubMed (Select 11239016)

1.

Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment.

Locatelli F, Bommer J, London GM, Martín-Malo A, Wanner C, Yaqoob M, Zoccali C.

Nephrol Dial Transplant. 2001 Mar;16(3):459-68. Review.

2.

[Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].

Del Vecchio L, Pozzoni P, Limardo M, Caruso S, Fortunato M, Pontoriero G, Locatelli F.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:25-32. Italian.

PMID:
17922444
3.

[Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].

Portolés J, López-Gómez JM, Aljama P.

Nefrologia. 2005;25(3):297-306. Spanish.

PMID:
16053011
5.

[Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].

Ravera M, Paoletti E.

Ital Heart J Suppl. 2004 Jun;5(6):436-44. Review. Italian.

PMID:
15471148
6.

Hypertension and cardiovascular risk assessment in dialysis patients.

Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M; Accorde Programme.

Nephrol Dial Transplant. 2004 May;19(5):1058-68. Epub 2004 Mar 5. Review.

7.

Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.

Locatelli F, Cannata-Andía JB, Drüeke TB, Hörl WH, Fouque D, Heimburger O, Ritz E.

Nephrol Dial Transplant. 2002 May;17(5):723-31. Review.

8.

Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.

Gadallah MF, el-Shahawy M, Andrews G, Ibrahim M, Ramdeen G, Hanna D, Gorospe W, Morkos A, Abbassian M, Moles K.

Adv Perit Dial. 2001;17:29-36.

PMID:
11510292
9.

The beneficial effects of intervention in early renal disease.

Portolés J.

Nephrol Dial Transplant. 2001;16 Suppl 2:12-5. Review.

10.

[Cardioprotection: an essential component for predialysis chronic renal failure treatment].

Jungers P, Qualim Z, Nguyen-Khoa T, Massy Z, London G.

Nephrologie. 2003;24(2):79-88. Review. French.

PMID:
12723513
11.

Cardiovascular disease in patients with chronic kidney disease.

Jaradat MI, Molitoris BA.

Semin Nephrol. 2002 Nov;22(6):459-73. Review.

PMID:
12430090
12.

[Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy].

Cases A, Vera M, López Gómez JM.

Nefrologia. 2002;22 Suppl 1:68-74. Review. Spanish.

PMID:
11987673
13.

Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.

Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2003 Jul;18(7):1272-80. Review.

15.

What have we learned from the current trials?

Abbott KC, Bakris GL.

Med Clin North Am. 2004 Jan;88(1):189-207. Review.

PMID:
14871059
16.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly.

Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review.

PMID:
17182241
17.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
18.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

PMID:
19018737
19.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk